Current Pharmaceutical Design

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back Subscribe

Novel Targets for Cardiac Antiarrhythmic Drug Development

Author(s): John Christian Hesketh, Daniel Herrera, Stephen Zicha and Stanley Nattel

Volume 11, Issue 15, 2005

Page: [1959 - 1974] Pages: 16

DOI: 10.2174/1381612054021051

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Cardiac arrhythmias remain a major source of morbidity and mortality in developed countries. Antiarrhythmic drug therapy was traditionally the mainstay of cardiac arrhythmia treatment; however, drug therapy of cardiac arrhythmias has been plagued by incomplete efficacy and by potentially serious adverse reactions, of which the most worrisome has been a potential for malignant proarrhythmia and related effects to increase cardiac mortality. This article reviews the principal arrhythmia mechanisms and their ionic determinants, and discusses potential innovative approaches to new antiarrhythmic drug development, including the consideration of novel ionic targets, potential biophysical approaches and non-channel components involved in composing the arrhythmic substrate.

Keywords: sinoatrial node (san), pacemaker, re-excitation, early afterdepolarizations(eads), sarcoplasmic reticulum (sr), automaticity, sodium current, channels, ultra rapid delayed rectifier, antiarrhythmic therapy


Rights & Permissions Print Cite